NLRP3/URAT1-IN-1 is an orally active dual inhibitor targeting NLRP3 and URAT1, with an IC50 of 3.81 μM. This compound effectively inhibits IL-1β release in LPS- and ATP-stimulated mouse bone marrow-derived macrophages, demonstrating an IC50 of 2.61 μM. In vivo studies reveal that NLRP3/URAT1-IN-1 significantly reduces serum uric acid levels and mitigates liver and kidney damage in models of acute hyperuricemia. This reagent is essential for investigating the pathophysiology of gout and hyperuricemia.
NLRP3/URAT1-IN-1 is an orally active dual inhibitor targeting NLRP3 and URAT1, with an IC50 of 3.81 μM. This compound effectively inhibits IL-1β release in LPS- and ATP-stimulated mouse bone marrow-derived macrophages, demonstrating an IC50 of 2.61 μM. In vivo studies reveal that NLRP3/URAT1-IN-1 significantly reduces serum uric acid levels and mitigates liver and kidney damage in models of acute hyperuricemia. This reagent is essential for investigating the pathophysiology of gout and hyperuricemia.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
